Track market-moving stories before they get noisy

Medifast (MED - Free Report) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +52.50%. A quarter ago, it was expected that this weight-loss company would post a loss of $0.67 per share when it actually produced a loss of $0.28, delivering a surprise of +58.21%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Medifast, which belongs to the Zacks Food - Miscellaneous industry, posted revenues of $72.05 million for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 5.89%. This compares to year-ago revenues of $89.41 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Medifast shares have added about 11.1% since the beginning of the year versus the S&P 500's gain of 11.4%.

What's Next for Medifast?While Medifast has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Medifast was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $59.98 million in revenues for the coming quarter and -$1.04 on $280.44 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Food - Miscellaneous is currently in the bottom 18% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Vital Farms (VITL - Free Report) , has yet to report results for the quarter ended September 2026. The results are expected to be released on November 3.

This company is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of -138.9%. The consensus EPS estimate for the quarter has been revised 10.4% lower over the last 30 days to the current level.

Vital Farms' revenues are expected to be $184.6 million, down 7.2% from the year-ago quarter.

The market expects Check Point Software (CHKP - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 2. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis data security company is expected to post quarterly earnings of $2.49 per share in its upcoming report, which represents a year-over-year change of -36.8%.

Revenues are expected to be $672.51 million, down 0.7% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.22% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Check Point?For Check Point, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.09%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Check Point will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Check Point would post earnings of $2.45 per share when it actually produced earnings of $2.55, delivering a surprise of +4.08%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Check Point doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today announced the launch of Via Retirement1, expanding its wealth business into the growing market for financial solutions in retirement. The new offering being made available in the US market brings together WTW’s deep retirement and investment expertise with personalized advice and technology, extending the company’s capabilities across the retirement lifecycle from savings accumulation through the transition into retirement.

As defined contribution plans have become the primary source of retirement savings for millions of workers, demand is growing for solutions that provide individuals with the option to convert accumulated retirement-focused investments into sustainable retirement income. While employers have invested significantly in helping employees save, much of that support ends when individuals retire from a company and enter a fragmented retail market. Via Retirement positions WTW to address this underserved need while helping employers extend the value of their retirement programs.

“Via Retirement builds on WTW’s decades of success supporting individuals to improve their financial security,” said Julie Gebauer, President of Health, Wealth & Career at WTW. “By combining our retirement and investment expertise with personalized advice and intuitive technology, Via Retirement addresses the growing market need to support the transition from retirement savings to living in retirement.” 

Via Retirement brings together real-time scenario modeling2, access to investment model portfolios, and personalized investment advice3 by investment adviser representatives, and a marketplace of annuity products4 supported by insurance brokers. Individuals can evaluate how decisions about retirement timing, goals, spending and income sources may affect their financial strategy and compare a range of retirement investment and income options in one place.

Via Retirement strengthens WTW’s proposition across the full retirement lifecycle, bringing together its capabilities with the goal of helping clients address evolving retirement needs and support better outcomes. Learn more here.

About WTW 

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success and provide perspective that moves you. 
Learn more at wtwco.com.

Media contacts

[email protected] / [email protected] 

1Via Retirement by WTW is the brand name of the combined investment advisory and fixed-insurance brokerage products and services that are offered by Willis Towers Watson Securities, LLC (“WTWS”) and Towers Watson Retiree Insurance Services, Inc (“TWRIS”). Investment advisory services, including the Via Retirement digital platform (the Platform”) and investment advice provided on the Platform, are offered and provided by Willis Towers Watson Securities, LLC (“WTWS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”). Registration does not imply a certain level of skill or training and does not constitute SEC approval, endorsement, or recommendation. WTWS provides investment advisory services to Clients through the Platform, combining a web-based financial planning and asset allocation tool with individualized guidance provided to Clients by investment adviser representatives (“IARs”). The Platform is intended to help Clients manage the complexity of retirement decision-making including whether to roll over their retirement plan into individual retirement account(s) (“IRA(s)”), establish an asset allocation appropriate to their risk and return objectives, and implement that allocation efficiently. WTWS and Towers Watson Retiree Insurance Services, Inc., an insurance brokerage firm (“TWRIS”), are commonly owned affiliates, and when a client’s recommended asset allocation includes a general allocation to fixed annuities, WTWS refers the Client to a TWRIS insurance agent to evaluate whether to purchase a fixed annuity, consistent with the Client’s best interest, a service for which TWRIS earns a commission on the resulting sale.  Fixed annuity transactions are not purchased through or part of WTWS’ advisory fees or services. Via Retirement by WTW is subject to eligibility requirements and is not available to all members of the general public. Purchase of products is not required to receive investment advice. Investments and annuities involve risks and may not be suitable for everyone. Investments will fluctuate and may lose value.

2Retirement projections are provided for informational purposes only, allocation advice results, income estimates and other financial illustrations are projections based on assumptions built into the project models and information provided by the user, may not reflect all relevant financial circumstances, and do not guarantee future results. Actual outcomes may differ materially. Information provided through the Platform is intended to support retirement-financial decisions. Neither the platform, service center representatives. Investment advisor representatives, nor insurance brokers provide legal, tax, or accounting advice. Service center representatives also do not provide investment advice or recommendations. Ongoing monitoring, discretionary investment management, and other advisory services are available only after you become a WTWS client and enter into the applicable advisory agreement with WTWS.

3Retirement outcomes are not guaranteed and will vary based on individual circumstances, financial decisions, investment performance, market conditions, and other factors.

4Products available through Via Retirement may be offered by affiliated or unaffiliated providers. Additional information regarding fees, compensation arrangements, conflicts of interest and product-specific disclosures will be provided before any purchase decision is made.

The ailing U.S. housing industry just got even more bad news, if that can be believed.

Pending home sales fell 7.3% in September from the previous month, according to the National Association of Realtors. The year-over-year decline was 11.3%. No region of the U.S was spared the carnage: the West had the largest decrease, followed by the South, the Midwest, and the Northeast.

So, you can't blame investors for avoiding homebuilder stocks. The State Street SPDR S&P Homebuilders ETF (XHB +0.06%), which tracks the S&P Select Industry Index, is down 10% over the past year. Some builders have fared much worse: Lennar (LEN +0.42%) has plummeted about 36% over that period.

LEN Lennar$85.28+$0.36 (+0.42%)

NYSE · As of 10:30 AM ET 10/26/26

Yet Berkshire Hathaway (BRKB +0.27%) is making large investments in the housing industry, including a significant acquisition and additional investments in Lennar -- a September stock purchase increased its stake in the company to 11%.

I think Berkshire's recent moves into the housing industry mean investors should take another look, but only if they're prepared to weather significant volatility and wait patiently for housing to recover. In fact, there may be a smart way to play the eventual housing recovery.

Image source: Getty Images.

So, what's ailing the housing industry? A lot, to say the least.

The industry has been struggling for years due to a massive shortage of housing supply and, more recently, soaring mortgage rates that have made home purchases impossible for many Americans. The average 30-year mortgage rate has climbed to almost 7.4% this year, more than one percentage point higher than at the beginning of 2026 and well more than double what the rate was five years ago.

The housing gap could be a huge opportunity The White House puts the housing gap -- the difference between the supply of and demand for available homes -- at 10 million houses.

I think Berkshire CEO Greg Abel sees that housing gap as a massive opportunity. So he's investing in homebuilders now when they're cheap. That includes a $53.9 million purchase of Lennar shares in September, taking its stake in the homebuilder to $2.2 billion, and the July acquisition of homebuilder Taylor Morrison for $6.8 billion. Berkshire says it will integrate Taylor's portfolio of housing brands with its own Clayton Properties Group, a collection of 15 regional builders, and the combined entity will make it the fourth-largest homebuilding operation in the U.S.

So, should ordinary investors be following Berkshire's lead into this beaten-down industry? Well, it's worth listening to what Abel recently said on CNBC: "We don't envision a quick recovery [in housing], but we do see it as an industry that we definitely want to be invested in, and we're invested in for the long-term."

Clearly, Berkshire has the patience and massive resources to wait for housing's recovery. And its recent purchases mean it will be locked and loaded with abundant homebuilding capacity when that happens.

BRKB Berkshire Hathaway$543.63+$1.44 (+0.27%)

NYSE · As of 10:30 AM ET 10/26/26

But with interest rates poised to rise as the Federal Reserve tightens financial conditions in response to elevated inflation, and bond yields -- which determine mortgage rates -- set to remain high as governments and AI infrastructure builders compete for capital, waiting for housing to recover could be a long and bumpy ride, to say the least.

I would suggest that investors interested in playing the long game on housing leave it to the experts: buy shares of Berkshire and profit from their patience and resources.

Have you assessed how the international operations of Snap-On (SNA - Free Report) performed in the quarter ended September 2026? For this tool and diagnostic equipment maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.

Our review of SNA's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

For the quarter, the company's total revenue amounted to $1.18 billion, experiencing a decline of 0.6% year over year. Next, we'll explore the breakdown of SNA's international revenue to understand the importance of its overseas business operations.

A Closer Look at SNA's Revenue Streams AbroadOf the total revenue, $186.8 million came from Europe during the last fiscal quarter, accounting for 15.8%. This represented a surprise of -7.12% as analysts had expected the region to contribute $201.11 million to the total revenue. In comparison, the region contributed $200.7 million, or 16.3%, and $181.5 million, or 15.2%, to total revenue in the previous and year-ago quarters, respectively.

Other International accounted for 11.5% of the company's total revenue during the quarter, translating to $135.6 million. Revenues from this region represented a surprise of +9.47%, with Wall Street analysts collectively expecting $123.87 million. When compared to the preceding quarter and the same quarter in the previous year, Other International contributed $131 million (10.6%) and $119.6 million (10%) to the total revenue, respectively.

Revenue Projections for Overseas MarketsThe current fiscal quarter's total revenue for Snap-On, as projected by Wall Street analysts, is expected to reach $1.26 billion, reflecting an increase of 2.6% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Europe is anticipated to contribute 16.7% or $211.2 million, and Other International 10.1% or $128.03 million.

For the full year, the company is expected to generate $4.92 billion in total revenue, up 3.7% from the previous year. Revenues from Europe and Other International are expected to constitute 16.8% ($828.21 million), and 10.3% ($505 million) of the total, respectively.

Key TakeawaysRelying on global markets for revenues presents both prospects and challenges for Snap-On. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.

Snap-On currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Assessing Snap-On's Stock Price Movement in Recent TimesOver the past month, the stock has seen a decline of 3.3% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 1.2%. The Zacks Consumer Discretionary sector, Snap-On's industry group, has ascended 4.8% over the identical span. In the past three months, there's been a decline of 13% in the company's stock price, against a rise of 2.5% in the S&P 500 index. The broader sector has increased by 2.8% during this interval.

The upcoming report from Emcor Group (EME - Free Report) is expected to reveal quarterly earnings of $8.33 per share, indicating an increase of 26.8% compared to the year-ago period. Analysts forecast revenues of $5.2 billion, representing an increase of 20.9% year over year.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

In light of this perspective, let's dive into the average estimates of certain Emcor Group metrics that are commonly tracked and forecasted by Wall Street analysts.

According to the collective judgment of analysts, 'Revenues- United States electrical construction and facilities services' should come in at $1.77 billion. The estimate points to a change of +38% from the year-ago quarter.

Analysts forecast 'Revenues- United States industrial services' to reach $328.50 million. The estimate indicates a year-over-year change of +14.5%.

The consensus among analysts is that 'Revenues- United States building services' will reach $841.50 million. The estimate indicates a year-over-year change of +3.4%.

Analysts' assessment points toward 'Revenues- United States mechanical construction and facilities services' reaching $2.32 billion. The estimate suggests a change of +30.6% year over year.

View all Key Company Metrics for Emcor Group here>>>

Over the past month, shares of Emcor Group have returned -15% versus the Zacks S&P 500 composite's -1.2% change. Currently, EME carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

SummaryAlnylam Pharmaceuticals, Inc.'s shares remain under pressure.On October 23, Alnylam reported promising clinical data for brezosiran, its investigational treatment for Huntington’s disease.Second-quarter Amvuttra sales surged 105.7% year-on-year to approximately $1.1 billion.Wall Street’s average price target for ALNY stands at $367.78, according to Seeking Alpha, implying 64.17% upside.In this article, I outline additional reasons why I believe Alnylam offers an attractive long-term risk/reward profile. Liudmila Chernetska/iStock via Getty Images

Alnylam Pharmaceuticals, Inc. (ALNY) is my favorite player in the RNAi therapeutics market.

I added it to my watchlist on July 30th, when its stock fell 30% to the -2σ band formed from the VWAP, $198.9, following a mixed

3.65K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New platform connects domain experts with mission-critical AI work as companies compete for the human expertise needed to move AI from innovation to execution  | Source: EXL

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- iMerit, an EXL company, today announced the launch of its iMerit Scholars platform, designed to seamlessly manage hundreds of thousands of global domain experts (Scholars) who work on fine-tuning, evaluation and validation of generative AI models. This represents the first major launch since EXL (Nasdaq: EXLS) acquired iMerit in July to accelerate the progression of frontier AI into regulated enterprises.

The launch comes as the AI talent war heats up across generative and physical AI. The iMerit Scholars program already brings together a curated global community of 30,000 domain experts and linguists to support advanced model training, evaluation, validation and safety across specialized fields. The new iMerit Scholars platform provides a unified system to recruit, onboard, curate, assign, manage, engage, pay, and retain these experts at scale. It is powered by iMerit’s proprietary Ango Hub, which allows customers and experts to collaborate on complex multimodal data to generate highly curated and validated training artifacts for high-stakes models. 

“iMerit has always differentiated itself by a curated, people-first approach. We’re seeing that become even more important as we scale up to help the frontier labs,” said Radha Basu, executive vice president, head of iMerit at EXL. “The next phase of the GenAI race is about creating a painless and supportive infrastructure so that these highly capable specialists can enjoy their work and give their best. Scaling high quality and high engagement is mainly a human capital opportunity, backed by enabling technology. The iMerit Scholars platform is designed to create a seamless experience for top-notch talent to continue building and improving the next generation of AI.”

“Now, as a part of EXL, we are expanding from the creation of models in frontier labs to the implementation of model workflows in highly regulated enterprises in banking, healthcare and insurance. Once again, we find that trust, safety, and last-mile customization will dictate the success of AI projects in these sectors. We need people who are knowledgeable enough not just to teach models, but to prove them wrong and correct them. That parallel human authority is what will help move AI from innovation to trusted execution,” added Basu.

Leveraging Trolley’s global payouts platform, iMerit Scholars incorporates compliance and global secure payments to create a mutually beneficial environment for customers and experts. 

The iMerit Scholars program was built to meet the need for structured reasoning, domain nuance, and ongoing evaluation across high-stakes use cases in healthcare, physical AI, finance, and foundation models. The iMerit Scholars community brings together over 30,000 invited and vetted professionals from 118 countries representing 106 languages across fields such as medicine, mathematics, agriculture, linguistics, and autonomous systems. iMerit works with them to test, challenge, and “torment” models, helping improve performance in real-world conditions through techniques like RLHF, red-teaming, Q&A prompting, chain-of-thought tracing, and evaluation.

The iMerit Scholars platform matches experts with projects aligned to their specialization, enabling more consistent engagement and higher-quality outcomes. iMerit Scholars platform also introduces new capabilities to support this evolving workforce model, including:

Expert matching based on domain specialization and cognitive skill setsSecure, compliant workflows for sensitive data environmentsGlobal payments and workforce infrastructure through TrolleyIntegrated tooling for training, evaluation, and model feedback loops For experts, iMerit Scholars platform represents a move from fragmented experiences to a meaningful, ongoing relationship.

“Working with AI in this way feels like contributing to something foundational,” said Pavel Kopach, M.D. Department of Pathology, Beth Israel Deaconess Medical Center, and iMerit Scholar in Healthcare AI. “You’re not just labeling data, you’re helping shape how these systems reason and behave in your field. That’s both challenging and incredibly rewarding.”

To learn more about iMerit, an EXL company, visit iMerit.ai.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 68,000 employees spanning six continents. For more information, visit www.exlservice.com.

Media Contact: [email protected] 

Bank of Hawaii (BOH - Free Report) came out with quarterly earnings of $1.49 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $1.2 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -1.97%. A quarter ago, it was expected that this bank holding company would post earnings of $1.46 per share when it actually produced earnings of $1.47, delivering a surprise of +0.68%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Bank of Hawaii, which belongs to the Zacks Banks - West industry, posted revenues of $200.11 million for the quarter ended September 2026, missing the Zacks Consensus Estimate by 1.51%. This compares to year-ago revenues of $182.64 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Bank of Hawaii shares have added about 3.3% since the beginning of the year versus the S&P 500's gain of 11.4%.

What's Next for Bank of Hawaii?While Bank of Hawaii has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Bank of Hawaii was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.57 on $206.97 million in revenues for the coming quarter and $5.88 on $803.74 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - West is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Hope Bancorp (HOPE - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2026. The results are expected to be released on October 28.

This bank holding company is expected to post quarterly earnings of $0.30 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has been revised 1.9% higher over the last 30 days to the current level.

Hope Bancorp's revenues are expected to be $152.6 million, up 7.4% from the year-ago quarter.

Exelon reports earnings before the open on Oct. 30, and buried inside the call is a transmission pipeline question that could shift how Wall Street prices this utility for years to come.

Exelon (NASDAQ:EXC | EXC Price Prediction) reports third-quarter results before the open on Friday, Oct. 30. Shares trade at $44.42, about 12.6% below $50. I think data center demand is the driver that could close that gap.

Steady Guidance After a Stormy Summer
Last quarter, Exelon posted adjusted operating earnings of $0.43 per share and confirmed full-year guidance of $2.81 to $2.91. Management aims to land “at the midpoint or better.” Jeanne Jones said the third quarter should represent about 27% of that midpoint.

Storms, weather, and a PECO employee strike in early July shaped that outlook. ComEd alone faced 16 major weather events. Exelon also withdrew its PECO rate case without cutting planned capital.

The stock rose 9.17% over the past month and 4.74% year to date, but remains down 3.24% over the past year. Analysts lowered their third-quarter EPS average from $0.8746 90 days ago to $0.7951.

Wall Street Expects a Lighter Third Quarter

Metric
Consensus
Year-Ago Actual
YoY Change

Q3 2026 EPS
$0.7951
$0.86
-7.5%

Q3 2026 Revenue
$6.82B
$6.705B
+1.7%

FY 2026 EPS
$2.8567
$2.77
+3.1%

FY 2026 Revenue
$25.5B
$24.26B
+5.1%

Gigawatts Must Turn Into Signed Contracts
Transmission is the hidden driver. Exelon cut its data center pipeline to 36 gigawatts from 43 gigawatts after a stricter review, yet kept its $41 billion capital plan through 2029 unchanged. 4 gigawatts carry signed transmission security agreements supported by $1 billion of collateral. The focus turns to how much of the remaining 25 gigawatts under review changes into secured commitments.

Management also sees a $12 billion to $17 billion transmission opportunity beyond the plan. Two MISO Tranche 2.1 bids with Invenergy should get answers in the fourth quarter, and a 500-megawatt New Jersey battery project adds about $1 billion not yet in the plan.

PJM’s strain supports the case. Capacity prices cleared at the $330 per megawatt-day cap for a third straight auction, and PJM’s simulation showed ComEd clearing near $777 without it. Regulatory timing is another factor to watch: an order on ComEd’s $15.3 billion grid plan is expected by December 15, while BGE’s $156.1 million request waits a January 2027 decision.

Funding risk looks contained. Exelon completed about 86% of its 2026 debt financing and priced all 2026 equity needs.

Why Transmission Could Re-Rate This Utility
Exelon beat EPS estimates in every quarter from Q2 2024 through Q4 2025, and a softer third quarter already sits in consensus. The path toward $50 runs through rate base. If management turns more of the pipeline into signed, collateral-backed load and holds growth near the top of its 5% to 7% range, I think investors will start valuing Exelon as a grid growth story.

Contact [email protected] for any questions or corrections.

New York, New York--(Newsfile Corp. - October 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Azenta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/azenta-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On August 24, 2026, Azenta filed with the SEC a current report on Form 8-K which stated that on "August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the "Company") and as a member of the Company's Board of Directors (the "Board"), effective as of August 22, 2026 (the "Effective Date")."

On this news, Azenta's stock fell 12% on August 24, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320811

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways Raymond James' Q4 earnings are projected to rise 5.5%, with revenues expected to grow 12.3% year over year.RJF's trading revenues are poised to gain from heightened market volatility and increased client activity.RJF's investment banking fees are expected to fall 4.9%, while NII is projected to rise 2.9%.
Raymond James (RJF - Free Report) is set to announce fourth-quarter and full-year fiscal 2026 (ended Sept. 30) results on Oct. 28, after market close. The company’s quarterly earnings and revenues are expected to have risen on a year-over-year basis.

In the last reported quarter, RJF’s earnings surpassed the Zacks Consensus Estimate. Results benefited primarily from an increase in revenues to record levels and robust growth in the assets under administration balance. However, higher expenses were the undermining factor.

Raymond James has an impressive earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, with the average beat being 6.67%.

The Zacks Consensus Estimate for the company’s fiscal fourth-quarter earnings is pegged at $3.28, unchanged over the past week. The figure indicates an increase of 5.5% from the year-ago quarter.

The consensus estimate for sales of $4.19 billion suggests 12.3% year-over-year growth.

Management expects fiscal third-quarter asset management and related administrative fees to grow 11% sequentially, driven by higher Private Client Group assets and fee-based accounts balance at quarter end.

Factors to Influence Raymond James’ Q4 EarningsInvestment Banking (IB) Fees: After an impressive performance in the last few quarters, global deal-making activity moderated in the September quarter, weighed down by elevated interest rates, persistent inflation and geopolitical uncertainties that complicated valuations and deal negotiations. Still, strategic buyers continued to pursue acquisitions to strengthen scale, operational resilience and supply-chain security amid a challenging business environment. So, overall global mergers and acquisitions (M&As) volume and value were muted as only a handful of big transactions dominated the space. This is expected to have hurt RJF’s advisory fees in the quarter.

IPO activity remained robust in the to-be-reported quarter, with proceeds climbing to a five-year high, despite a year-over-year decline in the number of deals. Meanwhile, global equity and debt issuance activity lost momentum as geopolitical uncertainties, persistent inflation and fluctuating energy prices dampened investor risk appetite. So, RJF’s underwriting fees are expected to have declined on a year-over-year basis.

The Zacks Consensus Estimate for the company’s total IB fees for the fiscal fourth quarter is pegged at $300.5 million, indicating a 4.9% decrease on a year-over-year basis.

Trading Revenues: The performance of RJF’s trading business is expected to have been strong in the to-be-reported quarter, supported by increased client activity and market volatility. Trading conditions were shaped by evolving expectations surrounding artificial intelligence, ongoing geopolitical tensions, persistent inflationary pressures and a more hawkish Federal Reserve. These factors contributed to heightened volatility across equities and other asset classes, including commodities, fixed income and foreign exchange.

Net Interest Income (NII): In the to-be-reported quarter, the Fed raised interest rates by 25 basis points to 3.75-4.00% for the first time in more than three years because of persistently high inflation. However, this is less likely to have affected Raymond James’ NII numbers much in the quarter.

The lending scenario is likely to have normalized in the September-end quarter, which, along with stabilizing funding/deposit costs, is expected to have offered much-needed support to RJF’s NII.

The Zacks Consensus Estimate for NII is pegged at $567.1 million, indicating a year-over-year rise of 2.9%.

Based on static interest rates and assuming unchanged quarter-end balances and net of the fiscal fourth-quarter fee billing collection of $2.1 billion, the company expects the aggregate of NII and Raymond James Bank Deposit Program (RJBDP) third-party fees in the fourth fiscal quarter to be flat sequentially.

Expenses: Raymond James consistently hires advisors and invests in franchises. Thus, overall expenses are expected to have increased in the to-be-reported quarter. Due to a highly competitive environment and inflationary pressure, expenses are likely to have risen.

For fiscal 2026, management expects non-compensation expenses, excluding the bank loan loss provision for credit losses, unexpected legal and regulatory items, and non-GAAP adjustments to be $2.3 billion, representing 8% year-over-year growth.

What the Zacks Model Unveils for Raymond JamesAccording to our proven model, the chances of RJF beating the Zacks Consensus Estimate for earnings this time are low. This is because it does not have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better.

You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Earnings ESP: The Earnings ESP for Raymond James is -0.82%.

Zacks Rank: The company currently has a Zacks Rank #3.

Finance Stocks Worth ConsideringHere are a couple of finance stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around.

Invesco (IVZ - Free Report) is scheduled to announce quarterly numbers on Oct. 27. The company has an Earnings ESP of +0.10% and carries a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Quarterly earnings estimates for Invesco have been revised marginally upward to 75 cents over the past week.

The Earnings ESP for Prosperity Bancshares (PB - Free Report) is +0.04%, and it carries a Zacks Rank #3 at present. The company is slated to report third-quarter 2026 results on Oct. 28.

Over the past seven days, the Zacks Consensus Estimate for Prosperity Bancshares’ quarterly earnings has been unchanged at $1.63 per share.

SummaryCoreWeave remains a Strong Buy despite a reduced 2027 price target of $179, reflecting higher unsecured debt costs and increased dilution risk.CRWV’s balance sheet repricing centers on $16.6B in unsecured debt now yielding close to 15%, impacting valuation multiples and equity funding requirements.Capacity is sold out with a $103.7B backlog, but 2027 funding needs require raising ~$33B, making financing—not demand—the critical variable for equity value.I am closely monitoring upcoming unsecured or convertible financings, at-the-market equity sales, EBITDA margins, and progress toward an investment-grade rating. pingingz/iStock via Getty Images

I have covered CoreWeave, Inc. (CRWV) twice, initiating with a strong buy and a roughly $250 price target in early July and maintaining both after the second-quarter results, and this piece is prompted by the 14 October selloff, in which the shares fell

106 Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRWV, NBIS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bitmine repurchased 2.04 million shares in the past week Bitmine has repurchased a cumulative 22.9 million shares so far in 2026, the largest ever crypto treasury company equity buyback executed Bitmine owns 4.95% of the total ETH coin supply of 122.2 million Bitmine is 99% of the way to the 'Alchemy of 5%' in just 15 months Bitmine released Chairman's Message on October 7 titled "Crypto Bull Underway — This Cycle Likely the Largest" Bitmine was added to the Russell 1000 Large-cap index on June 26, 2026 Bitmine's Series A Preferred Stock is trading on the NYSE under the symbol BMNP Bitmine has 5,227,037 staked ETH, representing $12.3 billion at $2,356 per ETH. MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors Bitmine owns $76 million of Eightco (NASDAQ: ORBS), now one of the only publicly listed equities in the world to provide investors indirect exposure to OpenAI Bitmine Crypto + Total Cash Holdings & Marketable Securities + "Moonshots" total $15 billion, including 6.05 million ETH tokens, total cash & marketable securities of $514 million, and other crypto holdings Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH NORWALK, Conn.

Schemes expected to become effective October 27, 2026; new Critical Metals Corp shares expected to begin trading on Nasdaq November 6, 2026  | Source: Critical Metals Corp

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals exploration and mining company, today announced that the Supreme Court of Western Australia (the “Court”) has approved the Company’s proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium”).

Under the proposed transaction, Critical Metals Corp would acquire 100% of the issued share capital of European Lithium and all of European Lithium’s listed options by way of Court-approved schemes of arrangement under Part 5.1 of the Australian Corporations Act 2001 (Cth), comprising a scheme between European Lithium and its shareholders (the “Share Scheme”) and a scheme between European Lithium and the holders of its listed options (ASX: EUROC) (the “Option Scheme”, and together with the Share Scheme, the “Schemes”). The consideration payable under each Scheme is to be satisfied by the issue of new ordinary shares in Critical Metals Corp.

Court Approval

European Lithium has announced that on October 26, 2026, the Court made orders approving the Schemes. The approval follows the vote by European Lithium shareholders and option holders in favor of the Schemes on October 22, 2026.

Critical Metals Corp intends to rely on the Court’s approval of the Schemes to qualify for the exemption from registration under section 3(a)(10) of the U.S. Securities Act of 1933, as amended, in connection with the issue of new Critical Metals Corp shares under the Schemes.

Effective Date and Implementation

The Schemes will become legally effective once an office copy of the Court orders is lodged with the Australian Securities and Investments Commission, which European Lithium expects to do on October 27, 2026. Trading in European Lithium shares and options on the ASX is expected to be suspended from the close of trading that day.

The remaining key dates are expected to be:

October 27, 2026: Effective date and last day of trading of European Lithium shares and options on the ASXOctober 29, 2026: Record date for entitlements to the scheme considerationNovember 5, 2026: Implementation date, issue of new Critical Metals Corp shares to European Lithium securityholdersNovember 6, 2026: New Critical Metals Corp shares expected to begin trading on Nasdaq, and European Lithium removed from the ASX Official List All dates refer to time in Perth, Western Australia, are indicative only and subject to change. Any changes will be announced by European Lithium on the ASX. For further details, including the full timetable and next steps, please refer to European Lithium’s announcement to the ASX, “Court Approval of Schemes,” dated October 26, 2026.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next-generation technologies for Europe and its Western world partners. Its flagship Project, Tanbreez, is one of the world's largest rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations, including with respect to the proposed acquisition of European Lithium and the anticipated timetable for and implementation of the Schemes. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: [email protected]
Media: [email protected]

Elon Musk's Space Exploration Technologies (SPCX +1.89%), better known as SpaceX, has spent 2026 rewriting Wall Street's record books. Its June 12 initial public offering (IPO) raised $85.7 billion, including the underwriters' overallotment, and valued SpaceX at $1.77 trillion. Both are never-before-seen figures.

But SpaceX's history-making moments aren't always beneficial to its investors. While early investors have made a fortune, retail investors may pay the price for this success.

Image source: Getty Images.

Space Exploration Technologies' debut as a public company has hardly been conventional. In addition to pricing its shares several days before its June 12 debut, the company's prospectus outlined a staggered and accelerated share lockup period for early-release-eligible insiders.

Typically, companies going public prevent their insiders (high-ranking executives, board members, and early investors) from selling shares for 180 calendar days after the IPO. This ensures that insiders don't take advantage of retail investor euphoria early on.

However, SpaceX is allowing some of its insiders to sell their shares at several earnings- and time-based events through mid-December. CEO Musk, who's SpaceX's largest shareholder, is not among these early-release-eligible insiders.

Great look at the SpaceX shares unlock schedule as well as the potential passive buying schedule from @JSeyff @FrancisSharoon Depending on the early post-IPO returns, this could really play with and disperse the returns of "passive" funds (which is why there's arguably no such thing as passive). $SPCX

— Eric Balchunas (@EricBalchunas) May 28, 2026
Two business days after each of SpaceX's quarterly earnings reports, up to 911.5 million shares became eligible for sale. With the company unveiling its third-quarter operating results on Oct. 20, roughly 911.5 million shares became newly eligible for sale on Oct. 22.

Several time-based events also allow insiders to sell approximately 319 million shares each time. These events occur on calendar days 70, 90, 105, 120, 135, and 180. Given that calendar day 135 landed on a weekend (Oct. 24), today, Oct. 26, marks the release of another 319 million shares for sale by early-release-eligible insiders.

Image source: Getty Images.

We're witnessing a dubious wealth transfer in real timeBut this ongoing and accelerated share lockup period for select insiders isn't the only dubious history being made by Musk's company.

When Space Exploration Technologies went public, it sold roughly 555.6 million shares. While this might sound like a lot, it represents less than 5% of SpaceX's outstanding shares (OS). Usually, private companies going public sell anywhere from 10% to 25% of their OS.

SpaceX selling such a small percentage of its OS created a favorable environment for its stock in the weeks after its IPO. Gaining fast-track entry into the Nasdaq-100, Russell 1000, and Russell 3000 meant that passive funds scooped up a significant portion of the company's float (tradable shares). This artificially low float initially buoyed SpaceX's stock.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

However, with each earnings- and time-based insider share-unlock event, SpaceX's float is rapidly rising. Although this doesn't guarantee that insiders are cashing out, keep in mind that the overwhelming majority of these early investors haven't had any avenues to cash in their chips for years, if not a decade.

What we're effectively witnessing with each successive share-unlock event is the greatest wealth transfer in Wall Street's storied history, from retail investors to SpaceX's early-release-eligible insiders. Given the laundry list of unknowns surrounding SpaceX, including the sustainability of its operating model amid its enormous cash needs, it wouldn't be surprising to see insiders ramp up their selling and weigh on the company's stock.

SummaryTesla, Inc.'s growing EV backlog amid elevated fuel prices and expanding, high-margin FSD adoption underscore TSLA's near-term thesis.As the CEO feeds the Tesla - SpaceX merger exuberance, the two entities' estimated 2026 Price/Sales of 22.19x is expensive compared to NVDA (12.37x), AAPL (10.63x), and AMZN (3.23x).Regulatory/execution merger risks loom large, with a spin-off of TSLA's Chinese operations and a premium buyout price in cash/stock being likely outcomes.To deliver the "stratospheric growth," more capital and capex/cash flow pains may be necessary before the realization of the nascent robotaxi, robotics, and foundry opportunities.TSLA remains a Sell, with a prolonged/failed merger likely to trigger downside risks amid a pessimistic stock market environment. Devrimb/iStock via Getty Images

TSLA - SPCX Merger Exuberance Since my last Sell rating in July 2026, Tesla, Inc. (TSLA, TSLA:CA) has outperformed expectations by delivering a rich >20% rally against the wider market at a single-digits gain.

Part

16.31K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOG, NVDA, AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Car rental giant Turo will start advertising which Teslas on its marketplace are outfitted with the automaker’s advanced driver assistance system, Full Self-Driving (Supervised) — or FSD, a collaboration that could boost further adoption of the driving software.

Eligible Turo “hosts” who rent out their cars on the platform will also receive a free one-month trial of FSD. Turo said it is working with Tesla to directly access the automaker’s API to verify which cars have FSD enabled.

The announcement comes just a few days after Tesla offered updated figures that show the carmaker is finally getting more customers to pay for the software, which can handle most driving tasks but still requires human supervision.

Last week, Tesla revealed that around 1.7 million customers have paid for FSD globally, out of more than 10 million cars built and sold to date. The company said more than 75% of customers who took delivery of a car in North America during the third-quarter paid for an FSD subscription. That was a roughly 20% increase from the second quarter, though the company’s U.S. sales have been in decline.

Tesla has spent much of the last year re-working some of its showrooms to focus more on FSD as a selling point. In a post last week, the company’s chief executive Elon Musk said the effort is working.

“People are buying FSD with a car attached, not the other way around,” wrote Musk.

“Customers are now coming in and saying: ‘Can we get into an FSD drive?’ They’re not asking for [Model] 3, [Model] Y, or Cybertruck,” Tesla’s finance chief Vaibhav Taneja said on last week’s earnings call.

For Turo, the addition of FSD rentals gives the company a chance to boost what are already some of its most heavily-rented vehicles. Turo said Tesla’s Model 3 and Model Y are the third and fourth-most popular vehicles on its platform this year. “[T]his integration further increases host earning opportunities as interest in self-driving technology grows,” said Turo.

“This industry-first integration with Tesla is another example of how Turo is redefining what car rental and access can look like,” Turo chief executive Andre Haddad said in a statement. “Most travelers have had limited opportunity to experience driver’s assistance technology, but the demand is clear. Our own research shows that 55% of Americans are interested in driverless technology for travel, growing to 71% for Gen Z. Turo’s marketplace model is uniquely positioned to close the gap between consumer curiosity and hands-on access.”

Customers who rent an FSD-enabled Tesla through Turo will be served cautionary language that requires drivers to monitor the software, and be ready to take over at any moment. Drivers will also have the option to view a Tesla-created tutorial.

“When enabled, your vehicle will drive you almost anywhere with your active supervision, requiring minimal intervention,” a screenshot of the Turo app reads.

The listings themselves, meanwhile, allow owners to promote their cars as “Self-Driving,” according to another screenshot provided by Turo.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Sean O’Kane is a reporter who has spent a decade covering the rapidly-evolving business and technology of the transportation industry, including Tesla and the many startups chasing Elon Musk. Most recently, he was a reporter at Bloomberg News where he helped break stories about some of the most notorious EV SPAC flops. He previously worked at The Verge, where he also covered consumer technology, hosted many short- and long-form videos, performed product and editorial photography, and once nearly passed out in a Red Bull Air Race plane.

You can contact or verify outreach from Sean by emailing [email protected] or via encrypted message at okane.01 on Signal.

Exxon's refining business delivered a historic quarter, but crude prices moved sharply against it heading into the Oct. 30 earnings call. Find out which force came out on top and what it means for the stock's remarkable 13% run.

Exxon Mobil (NYSE:XOM | XOM Price Prediction) reports third-quarter results on Oct. 30. A projected $4.5 billion refining boost runs into lower average crude prices, and this report will show which force carried the quarter.

Refining Muscle Powered a Huge Second Quarter
Last quarter, Exxon earned $14.5 billion and generated $23.6 billion in operating cash flow while temporarily losing roughly 10% of upstream production to Middle East disruptions. Free cash flow exceeded $17 billion, and net debt fell by more than $7 billion.

Refining did the heavy lifting. About 3 million barrels a day of industry capacity sat idle because of the Strait closure, and CEO Darren Woods said on the July call that Exxon expects “a very robust refining market with very high margins.” Gulf Coast reliability exceeded 95%, and diesel output set a second-quarter record.

Shares have gained 13.63% over the past month, closing at $183.21 on Oct. 23.

Wall Street Expects Earnings to More Than Double

Metric
Consensus
Year-Ago
Growth

Q3 2026 EPS
$3.981
$1.88
111.76%

Q3 2026 Revenue
$104.03B
$85.29B
21.96%

FY 2026 EPS
$12.9051
$6.99
84.62%

FY 2026 Revenue
$421.33B
$332.24B
26.82%

The quarterly EPS consensus has rose from $3.2767 90 days ago.

Refining Gains Versus Crude and Derivative Drag
The net math is what matters. Energy Products should collect roughly $4.5 billion in added earnings, but lower average Brent prices could create a $1.3 billion upstream drag. An estimated $2.5 billion paper loss from derivative timing effects adds noise. Those timing effects cost $3.88 billion in the first quarter, so you should focus on underlying earnings.

Upstream volume is the second test. Guyana reached about 900,000 barrels per day and the Permian exceeded 1.8 million oil equivalent barrels per day last quarter. I want an update on the Errea Wittu FPSO, which management targeted for start-up by year-end, and on the Golden Pass LNG ramp.

Capital returns matter too. Exxon plans $20 billion in 2026 buybacks and has extended dividend growth to 43 consecutive years, the kind of run that puts it firmly in the Dividend Kings club we ranked by valuation in a free report. Structural cost savings reached $16.3 billion against a $20 billion target for 2030.

Finally, listen for management’s tone on windfall taxes. Rising refining profits have renewed scrutiny in Washington, and Exxon runs 850,000 barrels a day of capacity in the U.K. and Europe, where similar levies are under discussion.

A Real Test of Exxon’s Through-Cycle Pitch
Management has argued that Exxon can perform across market cycles. This quarter tests that claim directly, because refining, upstream growth and cost cuts must offset lower crude and complex derivative accounting. If underlying earnings hold up and buybacks stay on pace, the stock’s run has a stronger foundation. Keep an eye on fourth-quarter refining commentary, since that will shape whether the windfall lasts.

Contact [email protected] for any questions or corrections.

During its most recent fiscal quarter (Q2 2026, ended Aug. 2), Home Depot (HD -2.41%) collected $47.9 billion in net sales. This makes it the biggest home improvement chain in the world. Comparatively, smaller rival Lowe's generated $26 billion in revenue in its latest fiscal quarter.

This level of scale plays to the company's advantage. It supports brand recognition. A footprint of more than 2,300 stores results in unmatched distribution. And inventory availability is robust, driving demand from professional customers, an important group to cater to.

These traits help Home Depot report consistent profits, which directly benefits income investors. If you want to make $10,000 in yearly dividends from this retail stock, you need to own 1,073 shares. But is the company's payout safe?

Image source: The Motley Fool.

Home Depot's real story is dividend growth
In September, Home Depot paid its investors $2.33 per share. On an annualized basis, this amounts to $9.32. Therefore, you'd need 1,073 shares to bring in $10,000 in annual passive income. Based on the current stock price of $328, this would set you back about $352,000.

At 2.84%, the current yield is strong. This is a much better yield than what the S&P 500 (^GSPC -0.52%) offers. Some income investors want a bigger yield. After all, plenty of stocks pay more. And the 10-year U.S. Treasury yield is just under 5%, having surged over the past 12 months (as of Oct. 22).

But yield is only the starting point. Investors should also consider growth. Home Depot's payout has soared, putting more money in shareholders' pockets over time. The dividend has increased by 238% over the last 10 years, going from $0.69 per quarter to the current distribution of $2.33. And it's been 158 consecutive quarters that the business has made a payout.

If you bought the stock exactly 10 years ago, you would've captured a starting dividend yield of 2.1%. Patience paid off, though. On that same cost basis, Home Depot now generates a substantially better dividend yield of 7.1%. During that entire period, investors didn't have to do anything except sit still.

$319.83-$7.90 (-2.41%)

NYSE · As of 4:00 PM ET 10/23/26

The payout is on solid ground
In the past decade, Home Depot's stock has climbed 150%. As mentioned, the dividend has risen by 238% over the same period. Investors might wonder whether the latter's higher growth rate is a sign that this isn't a blue chip dividend stock. It's important to figure out whether the payout is safe.

Home Depot historically has had no issue reporting positive earnings. This is true even though occasionally, industry or macroeconomic conditions deteriorate. During the great financial crisis, for example, perhaps the worst housing meltdown ever, management continued to pay dividends. However, the leadership team temporarily paused implementing any payout hikes, which was the correct financial strategic move.

The current environment is also worth exploring. Following a post-pandemic growth spurt that pushed double-digit revenue gains in fiscal 2020 and fiscal 2021, Home Depot has experienced a slowdown. Revenue growth has been in the low single digits. And same-store sales are expected to rise by just 1% (at the midpoint) this fiscal year.

Less accommodative macroeconomic conditions, such as stubborn inflation and elevated interest rates, have pressured operations. Housing turnover has been at historic lows for years now. And more customers might be waiting to tackle expensive renovation projects and upgrades.

Even in this unfavorable environment, Home Depot is generating sizable free cash flow. And it has continued to raise the dividend payout. This should give investors confidence.

Nothing is guaranteed in the future, of course. But it's hard to argue with the track record. Home Depot should be viewed by investors as a high-quality business that offers a safe dividend payout.

Oracle is sitting on a record AI backlog that analysts say could justify nearly doubling the stock price, yet the company just posted negative free cash flow and its CFO cannot say when that changes. Something has to give.

Oracle (NYSE:ORCL | ORCL Price Prediction) trades at $126.08. Its record AI backlog and its debt-funded expansion are drawing the stock in opposite directions. Shares were recently caught up in a broader AI debt selloff.

Oracle sells databases and enterprise applications, and it now runs one of the fastest-growing AI cloud businesses. Cloud revenue reached $11.61B last quarter, up 62%, and now makes up 60% of total revenue. Paying for that growth drove quarterly capex to $28.5B and free cash flow to negative $5.4B. The stock is down 34.41% year to date.

A $664 Billion Backlog Priced at 18 Times Forward Earnings
Remaining performance obligations total $664B, up $209B year over year. Management expects “around half of our RPO to convert into sales over the next 36 months.” Customers signed more than $30 billion in new AI contracts, and most were structured as prepayments or bring-your-own-hardware deals. Cloud infrastructure revenue increased 121%. GPU use hit 97.9%, and renewals were priced at a 20% premium.

Operating leverage is showing up. Operating income rose 57.3% on 29.6% revenue growth. Guidance calls for at least $90B in fiscal 2027 revenue and $8.10 in non-GAAP EPS. Over the past 30 days, 35 analysts raised full-year estimates and only 1 cut them. A forward P/E of 18 and a PEG of 0.802 look cheap for that growth rate.

Interest Costs and Dilution Threaten Shareholder Returns
Free cash flow was negative $23.7B in fiscal 2026. Quarterly interest expense rose 55% to $1.43B. Total debt stands at $155.9B, and capital lease obligations add $30.6B. Oracle just finished a $20B at-the-market equity sale and plans to raise about $40B this fiscal year through debt and equity. Asked when free cash flow turns positive, CFO Hilary Maxson said, “We haven’t given a particular timeframe on that yet.”

A handful of very large AI contracts make up much of the backlog, and license revenue fell 15%. DA Davidson’s Gil Luria named data center execution and a leveraged balance sheet as the two biggest constraints. The market also punishes misses. Shares fell about 13% after a revenue miss last December.

Execution Is Strong, but Cash Flow Proof Is Still Missing
Execution has been strong. Oracle delivered 850MW of capacity and generated record operating cash flow of $23.1B. Funding remains unclear. Net cash capex could reach $70 billion this year, and management has given no date for positive free cash flow.

Oracle itself is the expansion story here, but it isn’t building alone. The companies that equip these data centers — providing electricity, cooling and network infrastructure — make up a trade of their own, and we covered seven of them in a free report: 7 Stocks Powering the AI Boom (That Aren’t Chipmakers).

The next earnings report tests cloud growth guidance of 65-71% and EPS guidance of $1.85-$1.93. Investors should also watch borrowing terms and progress at the New Mexico and Wisconsin sites.

Analysts See 87.6% Upside as the Stock Lags the S&P 500
The consensus target at $236.54 suggests a 87.6% gain from $126.08. Targets are only one data point. 43 analysts cover the stock:

Strong Buy: 7
Buy: 28
Hold: 7
Sell: 1

Oracle trades at 20 times trailing earnings and has a beta of 1.77. Over the past year, shares fell 54.35% while the S&P 500 rose 13.13%. Over the past month, Oracle dropped 12.42%, and the index slipped 1.02%.

Free Cash Flow Is the Missing Piece for Oracle
At $126.08, Oracle’s risks and rewards look balanced.

The backlog is real, and revenue from it is starting to show up. Yet the balance sheet takes on each new contract before shareholders see the cash. A stronger outlook needs two things: a clear date for positive free cash flow, and proof that customer prepayments are reducing outside funding needs. A weaker outlook would follow a revenue miss, slower cloud growth or expensive new debt.

Upside could arrive quickly. A turn in free cash flow could rerate the stock quickly at 18 times forward earnings. Dilution remains a risk, because more equity issue would dilute current holders. Each quarter, check RPO conversion, net capex and interest expense.

Oracle’s backlog makes the business more valuable, but until the funding gap closes, the funding gap remains the key variable for the stock.

Contact [email protected] for any questions or corrections.

AbbVie heads into its October 30 earnings report riding a 28% rally and fresh FDA approvals, but options traders are bracing for a 5% swing in either direction and the stock has a recent habit of selling off even on…

AbbVie (NYSE:ABBV | ABBV Price Prediction) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release. That leaves little room for a stumble.

Big Momentum Meets a Guidance Trim Last quarter, AbbVie posted adjusted EPS of $3.65 on revenue of $16.99 billion, up 10.2% year over year. Skyrizi grew 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion, which more than made up for a 35.9% slide in Humira.

Management still trimmed full-year adjusted EPS guidance to $13.87 to $14.07. The cut included $0.14 of dilution from the roughly $10.9 billion Apogee Therapeutics deal, partly offset by $0.10 of operational overperformance. Revenue guidance rose $300 million to about $67.6 billion.

Several catalysts have arrived since then. The FDA approved Juvmo (tavapadon) for Parkinson’s disease on September 28 and Skyrizi’s subcutaneous induction regimen for Crohn’s disease on October 23. Lutikizumab also posted positive Phase 3 results in hidradenitis suppurativa, and the stock gained 8.24% over the past month to $285.19.

Consensus Points to a Sharp Profit Rebound Analysts expect EPS to roughly double. The year-ago quarter included a $1.50 per-share acquired IPR&D charge, which inflates the comparison.

Metric Q3 2026 Consensus YoY Growth FY2026 Consensus YoY Growth Normalized EPS $3.7788 103.2% $13.9562 39.6% Revenue $17.35 billion 10.0% $67.63 billion 10.6% Immunology Pace and Apogee Math Will Set the Tone Skyrizi and Rinvoq now generate nearly half of revenue, and analysts expect Rinvoq to clear roughly $2.73 billion. In July, management raised Skyrizi’s full-year outlook to $21.7 billion and reported “absolutely no degradation” in new starts after a rival launch. Both trends should show up in the quarterly numbers.

Guidance is the second test. Consensus EPS of $3.7788 sits below management’s $3.84 to $3.88 target after eight downward revisions over 30 days.

That target excludes acquired IPR&D, which cost $0.58 per share through June, and includes partial-quarter Apogee dilution. The focus will be on confirmation that the deal closed and whether operational strength again offsets the drag on the full-year range.

Neuroscience grew 20.3% to $3.23 billion last quarter, and management expects Vyalev to reach blockbuster sales this year. Chief Commercial Officer Jeffrey Ryan Stewart said on the July call that the tavapadon ramp “will be modest at first.” Management expects Skyrizi’s new Crohn’s regimen to drive acceleration starting early in 2027.

Finally, track the drags. Imbruvica fell 29.4% and Juvederm slipped 6.0% in the second quarter, and the pace of Humira erosion still determines how much of the immunology gain reaches the top line.

A Premium Rally Needs Clean Execution AbbVie trades near 20x full-year consensus EPS, and recent history shows beats can still trigger selling. Shares fell 4.45% on earnings day after the Q3 2025 beat and 2.51% after the Q2 2026 beat. Positioning leans bullish, with a 0.59 put/call ratio on contracts expiring October 30. A raised outlook and a clean Apogee update would give this rally steadier ground.

Contact [email protected] for any questions or corrections.

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers, and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA's original procurement of the treatment in 2020.

Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S. government through 2031 and receive payment of approximately $270 million.

"Maintaining a ready supply of Inmazeb is exactly the kind of preparedness this country needs for the threats we can already see on the horizon," said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. "This extended agreement reflects the strength of our long-standing collaboration with BARDA and our shared commitment to ensuring that at-the-ready medicines are available whenever an Ebola outbreak occurs."

Maftivimab Development Program

Separately, Regeneron’s investigational maftivimab monotherapy is being added to the PARTNERS trial to assess use as a potential treatment in the current Bundibugyo virus disease outbreak

Maftivimab has demonstrated positive in vitro and non-human primate activity against Bundibugyo; preprint data now available

Separate from the Inmazeb procurement agreement, Regeneron is evaluating maftivimab, the most potent virus-neutralizing component of Inmazeb, as a potential treatment for Ebola disease caused by Bundibugyo virus, the orthoebolavirus driving the current outbreak in the Democratic Republic of the Congo (DRC) and for which there are no currently approved treatment options. Maftivimab has demonstrated strong efficacy against Bundibugyo virus in in vitro and non-human primate (NHP) studies, supporting its continued development as a monotherapy or combination treatment candidate. These data are now available in preprint on BioRxiv.org and pending peer review publication.

"Inmazeb was created by Regeneron scientists in record time using our proprietary VelociSuite® rapid-response technologies," said George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron. "We are now advancing maftivimab, which has already demonstrated positive results in non-human primates infected with Bundibugyo, so that we can bring another potential Ebola treatment forward as quickly as possible to help in the current outbreak. Regeneron's continued supply of Inmazeb to the U.S. government, our advancement of maftivimab and our partnerships to support frontline response capacity reflect the Company's long-term commitment to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks."

Based on in vitro and NHP efficacy studies, maftivimab is being added to the PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) clinical trial, which is evaluating potential treatments for Bundibugyo virus disease. PARTNERS is delivered through a global partnership of Ministries of Health, researchers, healthcare workers and international research and non-governmental organizations. The trial has been designed and is coordinated internationally by the Pandemic Sciences Institute, University of Oxford, and is being led nationally in the DRC by the Institut National de Recherche Biomédicale (INRB), supported by the Institute of Tropical Medicine (ITM), Antwerp. The trial is sponsored by the World Health Organization (WHO) and is made possible with the support of Africa CDC.

Regeneron also continues to support Afya Foundation’s emergency response efforts aimed at safeguarding frontline healthcare workers and strengthening healthcare system resilience during the current outbreak.

About Inmazeb
Inmazeb is approved by the U.S. FDA for the treatment of infection caused by Orthoebolavirus zairense (formerly known as Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. Inmazeb was created using Regeneron’s
VelocImmune® platform and associated VelociSuite® technologies. The treatment consists of three monoclonal antibodies that help neutralize the Ebola virus by blocking its ability to invade a patient’s cells and/or enlisting other immune cells to target infected cells and remove them from the body.

The safety and efficacy of Inmazeb was established through the 681-patient PALM Trial, which was independently conducted by the WHO, the U.S. National Institutes of Health and the INRB during the 2018 DRC outbreak of Ebola virus. In 2019, as reported in the New England Journal of Medicine, the PALM Trial was stopped early following a pre-specified interim analysis that showed the superiority of Inmazeb in preventing death versus two other investigational treatments.

Inmazeb was approved by the FDA in 2020, and in 2022, WHO published its first guidelines for Ebola virus therapeutics, which strongly recommends the use of Inmazeb for treatment of Ebola virus infection and calls on the global community to engage all possible mechanisms to improve access to life-saving Ebola disease medicines. In November 2023, Inmazeb became the first and only Ebola disease treatment to be prequalified by the WHO, certifying that the medicine meets WHO’s standards for quality, safety and efficacy and is considered “essential.”

Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Ebola virus disease outbreak caused by Orthoebolavirus zairense, including the DRC and Guinea. In September 2025, the company committed to donate up to 500 doses of Inmazeb to the WHO for exclusive use by governments of low- and lower-middle income countries that are most at-risk for Ebola disease outbreaks.1 In addition, Regeneron has worked with governments in higher- and middle-income countries to establish Inmazeb stockpiles.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201700016C and HHSO100201500013C. The contract and federal funding are not an endorsement of the product or company.

IMPORTANT SAFETY INFORMATION AND INDICATION WARNINGS AND PRECAUTIONS FOR INMAZEB

Hypersensitivity Reactions Including Infusion-Associated Events: Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following INMAZEB infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care.

Infusion could not be completed in 1% of subjects who received INMAZEB due to infusion-associated adverse events. The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events.

ADVERSE REACTIONS: The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea and vomiting. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection.

DRUG INTERACTIONS: INMAZEB may reduce the efficacy of live vaccine, therefore, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.

INDICATION
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Limitations of Use: The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding to use INMAZEB.

Please see accompanying full Prescribing Information for Inmazeb.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Inmazeb® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of infection caused by Orthoebolavirus zairense (also known as Ebola virus) as well as maftivimab as a potential treatment for Bundibugyo ebolavirus; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products (including Inmazeb) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates (such as maftivimab) and new indications for Regeneron’s Products; whether and the extent to which Regeneron will be able to deliver the additional treatment doses of Inmazeb set forth in its agreement with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (collectively, the "U.S. Government") discussed in this press release (the "Supply Agreement"), the amount of payments (if any) Regeneron may receive pursuant to the Supply Agreement, and whether the Supply Agreement is terminated by the U.S. Government or otherwise prior to completion; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025, and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Media Contact for Regeneron
[email protected]

Investor Contact for Regeneron
[email protected]

_________________
1 As defined by the World Bank based on gross national income per capita.

SBI Securities Co. Ltd. raised its holdings in Broadcom Inc. (NASDAQ:AVGO – Free Report) by 10.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,067 shares of the semiconductor manufacturer’s stock after purchasing an additional 6,443 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Broadcom were worth $24,607,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Marion Wealth Management grew its holdings in shares of Broadcom by 1.3% during the 3rd quarter. Marion Wealth Management now owns 4,878 shares of the semiconductor manufacturer’s stock worth $1,713,000 after purchasing an additional 61 shares during the period. Aire Advisors LLC increased its position in shares of Broadcom by 20.6% during the 3rd quarter. Aire Advisors LLC now owns 2,329 shares of the semiconductor manufacturer’s stock worth $818,000 after purchasing an additional 398 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Broadcom by 5.5% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 3,411 shares of the semiconductor manufacturer’s stock worth $1,198,000 after purchasing an additional 177 shares during the last quarter. Cypress Wealth Services LLC raised its holdings in Broadcom by 3.1% in the 3rd quarter. Cypress Wealth Services LLC now owns 13,390 shares of the semiconductor manufacturer’s stock valued at $5,032,000 after buying an additional 401 shares during the period. Finally, Woodward Diversified Capital LLC lifted its position in Broadcom by 1.8% in the third quarter. Woodward Diversified Capital LLC now owns 7,615 shares of the semiconductor manufacturer’s stock valued at $2,674,000 after buying an additional 131 shares during the last quarter. Institutional investors and hedge funds own 76.43% of the company’s stock.

Broadcom Price Performance AVGO stock opened at $321.68 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.50 and a quick ratio of 2.29. The firm has a market capitalization of $1.54 trillion, a P/E ratio of 41.08 and a beta of 1.46. The business’s 50-day moving average is $356.05 and its two-hundred day moving average is $384.74. Broadcom Inc. has a 1 year low of $289.96 and a 1 year high of $495.00.

Broadcom (NASDAQ:AVGO – Get Free Report) last announced its quarterly earnings data on Wednesday, September 2nd. The semiconductor manufacturer reported $3.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.22 by $0.10. Broadcom had a return on equity of 48.33% and a net margin of 42.94%. The business had revenue of $29.59 billion during the quarter, compared to analysts’ expectations of $29.24 billion. During the same quarter last year, the business posted $1.69 EPS. The business’s quarterly revenue was up 85.5% compared to the same quarter last year. Analysts anticipate that Broadcom Inc. will post 10.37 earnings per share for the current fiscal year. Broadcom Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Monday, September 21st were issued a $0.65 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $2.60 annualized dividend and a yield of 0.8%. Broadcom’s dividend payout ratio (DPR) is 33.21%.

Analyst Ratings Changes A number of equities research analysts have weighed in on the stock. Erste Group Bank reiterated a “hold” rating on shares of Broadcom in a research report on Tuesday, July 7th. Jefferies Financial Group started coverage on shares of Broadcom in a research note on Thursday, September 3rd. They issued a “buy” rating and a $550.00 price target on the stock. Raymond James Financial restated an “outperform” rating and issued a $475.00 price objective (up from $450.00) on shares of Broadcom in a report on Thursday, September 3rd. Citic Securities raised shares of Broadcom to a “buy” rating and increased their price objective for the stock from $450.00 to $525.00 in a research report on Tuesday, September 8th. Finally, Lake Street Capital upgraded shares of Broadcom to a “buy” rating in a report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, thirty-eight have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Broadcom presently has an average rating of “Moderate Buy” and an average target price of $529.17.

View Our Latest Stock Analysis on Broadcom

More Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: ETF investors bought approximately $89.8 million of Broadcom shares on October 21, signaling continued institutional demand. Broadcom Sees $89.8 Million in Net ETF Buying Positive Sentiment: Analysts continue to highlight Broadcom’s leadership in custom AI accelerators. Demand from major AI labs and hyperscalers, including Anthropic, OpenAI and Meta, supports management’s ambitious long-term AI semiconductor growth outlook. 3 Magnificent AI Chip Stocks Positive Sentiment: Tigress Financial initiated coverage with a Buy rating and a $600 price target, implying substantial upside from recent trading levels. Tigress Financial Broadcom Coverage Positive Sentiment: Broadcom launched Arcot Scam Defense, a real-time fraud-detection feature for digital payments. Strong initial pilot results could create incremental growth for its software and security businesses. Broadcom Debuts Arcot Scam Defense Neutral Sentiment: Broadcom remains the leading custom-chip design partner, but Alphabet is diversifying its TPU suppliers. Although Broadcom may lose market share, the overall AI accelerator market is expected to expand rapidly, potentially offsetting that loss. Broadcom AI Chip Business Risks Negative Sentiment: Investors are worried that customer-owned chip design and increased competition from MediaTek could reduce Broadcom’s role and margins in future AI programs. Alphabet’s supplier diversification is the clearest near-term risk. Broadcom AI Chip Business Risks Negative Sentiment: The broader market sell-off is weighing on AI stocks amid higher oil prices, inflation concerns and questions about whether massive data-center investments will generate sufficient returns. Technical commentary identifies the $320 area as an important support test. Broadcom Faces Critical $320 Test About Broadcom (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software products. Its semiconductor solutions support data center, networking, broadband, wireless communications, storage, industrial and other electronic applications.

The company’s semiconductor portfolio includes networking and switching components, custom accelerators, connectivity and wireless devices, broadband equipment, optical products, storage controllers and related infrastructure technologies.

Further Reading Five stocks we like better than Broadcom Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader? Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way Can Planet Fitness Get Its Growth Back in Shape? Want to see what other hedge funds are holding AVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc. (NASDAQ:AVGO – Free Report).

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

 | Source: Stryker Corporation

Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolioThe acquisition adds a commercialized rotator cuff augmentation technology to Stryker’s shoulder portfolioThe addition expands Stryker’s ability to support shoulder specialists across sports medicine and shoulder care Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the FiberLocker® System.

The FiberLocker System is a commercialized rotator cuff augmentation technology designed to increase the biomechanical strength of the repair. The differentiated technology addresses an important clinical need in rotator cuff repair and expands Stryker’s ability to support shoulder surgeons with innovative solutions across the shoulder continuum of care.

“ZuriMED brings specialized expertise and a differentiated technology that complements our growing shoulder care capabilities,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “Together, we have an opportunity to advance the FiberLocker technology, expand access to innovative treatment options and deliver greater value for our customers and their patients.”

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead
Vice President, Investor Relations
[email protected]

For media inquiries:
Kim Montagnino
Vice President, Chief Communications Officer
[email protected]